Erratum for the Research Article “Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15” by T. Han, M. Goralski, N. Gaskill, E. Capota, J. Kim, T. C. Ting, Y. Xie, N. S. Williams, D. Nijhawan

In the Research Article “Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15,” the authors incorrectly stated that spliceostatin has been tested in clinical trials. Rather, E7107, a different small-molecule inhibitor of SF3B1, has been tested in clinical trials. The text in the Discussion section has been changed to reflect this. A new reference 45 [Y. Kotake et al., Nat. Chem. Biol. 3, 570 (2007)] has been provided to support the corrected text.